Annual report
6323.TEDINET S100Y5GM
Period2025-03-01 → 2026-02-28
Filed2026-05-22
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥128.8bn | 2025-03-01 → 2026-02-28 | Cons. | Net sales |
| Revenue | ¥124.4bn | 2024-03-01 → 2025-02-28 | Cons. | Net sales |
| Revenue | ¥93.2bn | 2023-03-01 → 2024-02-29v | Cons. | Net sales (5-year summary) |
| Revenue | ¥94.5bn | 2022-03-01 → 2023-02-28v | Cons. | Net sales (5-year summary) |
| Revenue | ¥67.0bn | 2021-03-01 → 2022-02-28v | Cons. | Net sales (5-year summary) |
| Operating income | ¥31.2bn | 2025-03-01 → 2026-02-28 | Cons. | Operating income |
| Operating income | ¥32.0bn | 2024-03-01 → 2025-02-28 | Cons. | Operating income |
| Ordinary income | ¥32.6bn | 2025-03-01 → 2026-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥35.5bn | 2024-03-01 → 2025-02-28 | Cons. | Ordinary income |
| Ordinary income | ¥27.1bn | 2023-03-01 → 2024-02-29v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥30.3bn | 2022-03-01 → 2023-02-28v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.8bn | 2021-03-01 → 2022-02-28v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥25.0bn | 2025-03-01 → 2026-02-28 | Cons. | Income before income taxes |
| Profit before tax | ¥32.6bn | 2024-03-01 → 2025-02-28 | Cons. | Income before income taxes |
| Net income (owners) | ¥19.0bn | 2025-03-01 → 2026-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥23.6bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥19.6bn | 2023-03-01 → 2024-02-29v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥21.4bn | 2022-03-01 → 2023-02-28v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.8bn | 2021-03-01 → 2022-02-28v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥17.5bn | 2025-03-01 → 2026-02-28 | Cons. | Profit loss |
| Net income | ¥23.1bn | 2024-03-01 → 2025-02-28 | Cons. | Profit loss |
| Total assets | ¥197.3bn | at 2026-02-28 | Cons. | Assets |
| Total assets | ¥187.7bn | at 2025-02-28 | Cons. | Assets |
| Total assets | ¥156.1bn | at 2024-02-29v | Cons. | Total assets (5-year summary) |
| Total assets | ¥126.5bn | at 2023-02-28v | Cons. | Total assets (5-year summary) |
| Total assets | ¥88.3bn | at 2022-02-28v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥57.3bn | at 2026-02-28 | Cons. | Liabilities |
| Total liabilities | ¥59.0bn | at 2025-02-28 | Cons. | Liabilities |
| Net assets / equity | ¥140.0bn | at 2026-02-28 | Cons. | Net assets |
| Net assets / equity | ¥128.7bn | at 2025-02-28 | Cons. | Net assets |
| Net assets / equity | ¥99.5bn | at 2024-02-29v | Cons. | Net assets |
| Net assets / equity | ¥74.8bn | at 2023-02-28v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥50.2bn | at 2022-02-28v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥74.3bn | at 2026-02-28 | Cons. | Cash and deposits |
| Cash and deposits | ¥63.0bn | at 2025-02-28 | Cons. | Cash and deposits |
| Cash & equivalents | ¥74.3bn | at 2026-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥61.3bn | at 2025-02-28 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥38.0bn | at 2024-02-29v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥28.3bn | at 2023-02-28v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥23.6bn | at 2022-02-28v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥31.2bn | 2025-03-01 → 2026-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥36.8bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥15.5bn | 2023-03-01 → 2024-02-29v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥1.9bn | 2022-03-01 → 2023-02-28v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥3.0bn | 2021-03-01 → 2022-02-28v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥3.3bn | 2025-03-01 → 2026-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥6.5bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.9bn | 2023-03-01 → 2024-02-29v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.2bn | 2022-03-01 → 2023-02-28v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥916m | 2021-03-01 → 2022-02-28v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥15.5bn | 2025-03-01 → 2026-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥9.2bn | 2024-03-01 → 2025-02-28 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥792m | 2023-03-01 → 2024-02-29v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥10.7bn | 2022-03-01 → 2023-02-28v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥3.6bn | 2021-03-01 → 2022-02-28v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥109.33 | 2025-03-01 → 2026-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥134.08 | 2024-03-01 → 2025-02-28 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥111.11 | 2023-03-01 → 2024-02-29v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥123.74 | 2022-03-01 → 2023-02-28v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.21 | 2021-03-01 → 2022-02-28v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥109.33 | 2025-03-01 → 2026-02-28 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥133.99 | 2024-03-01 → 2025-02-28 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥110.91 | 2023-03-01 → 2024-02-29v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥123.51 | 2022-03-01 → 2023-02-28v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥74.07 | 2021-03-01 → 2022-02-28v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥750.89 | at 2026-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥668.48 | at 2025-02-28 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥523.34 | at 2024-02-29v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥394.78 | at 2023-02-28v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥262.44 | at 2022-02-28v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 66.0% | at 2026-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 62.8% | at 2025-02-28 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.1% | at 2024-02-29v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 53.9% | at 2023-02-28v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 51.4% | at 2022-02-28v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 15.4% | 2025-03-01 → 2026-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 22.5% | 2024-03-01 → 2025-02-28 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 24.4% | 2023-03-01 → 2024-02-29v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 37.7% | 2022-03-01 → 2023-02-28v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 33.7% | 2021-03-01 → 2022-02-28v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 4,435 | at 2026-02-28 | Cons. | Number of employees |
| Employees | 4,402 | at 2025-02-28 | Cons. | Number of employees |
| Employees | 3,997 | at 2024-02-29v | Cons. | Number of employees |
| Employees | 4,372 | at 2023-02-28v | Cons. | Number of employees |
| Employees | 3,670 | at 2022-02-28v | Cons. | Number of employees |
| Revenue | ¥69.8bn | 2025-03-01 → 2026-02-28 | Standalone | Net sales |
| Revenue | ¥79.4bn | 2024-03-01 → 2025-02-28 | Standalone | Net sales |
| Revenue | ¥64.5bn | 2023-03-01 → 2024-02-29v | Standalone | Net sales (5-year summary) |
| Revenue | ¥62.9bn | 2022-03-01 → 2023-02-28v | Standalone | Net sales (5-year summary) |
| Revenue | ¥48.8bn | 2021-03-01 → 2022-02-28v | Standalone | Net sales (5-year summary) |
| Operating income | ¥18.0bn | 2025-03-01 → 2026-02-28 | Standalone | Operating income |
| Operating income | ¥19.6bn | 2024-03-01 → 2025-02-28 | Standalone | Operating income |
| Ordinary income | ¥19.3bn | 2025-03-01 → 2026-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥20.8bn | 2024-03-01 → 2025-02-28 | Standalone | Ordinary income |
| Ordinary income | ¥18.8bn | 2023-03-01 → 2024-02-29v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥13.9bn | 2022-03-01 → 2023-02-28v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥12.8bn | 2021-03-01 → 2022-02-28v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥11.9bn | 2025-03-01 → 2026-02-28 | Standalone | Income before income taxes |
| Profit before tax | ¥20.8bn | 2024-03-01 → 2025-02-28 | Standalone | Income before income taxes |
| Net income | ¥8.3bn | 2025-03-01 → 2026-02-28 | Standalone | Profit loss |
| Net income | ¥14.7bn | 2024-03-01 → 2025-02-28 | Standalone | Profit loss |
| Net income | ¥13.2bn | 2023-03-01 → 2024-02-29v | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.7bn | 2022-03-01 → 2023-02-28v | Standalone | Net income loss (5-year summary) |
| Net income | ¥9.2bn | 2021-03-01 → 2022-02-28v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥106.2bn | at 2026-02-28 | Standalone | Assets |
| Total assets | ¥109.0bn | at 2025-02-28 | Standalone | Assets |
| Total assets | ¥96.0bn | at 2024-02-29v | Standalone | Total assets (5-year summary) |
| Total assets | ¥74.0bn | at 2023-02-28v | Standalone | Total assets (5-year summary) |
| Total assets | ¥55.2bn | at 2022-02-28v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥41.8bn | at 2026-02-28 | Standalone | Liabilities |
| Total liabilities | ¥45.1bn | at 2025-02-28 | Standalone | Liabilities |
| Net assets / equity | ¥64.4bn | at 2026-02-28 | Standalone | Net assets |
| Net assets / equity | ¥63.9bn | at 2025-02-28 | Standalone | Net assets |
| Net assets / equity | ¥52.2bn | at 2024-02-29v | Standalone | Net assets |
| Net assets / equity | ¥37.3bn | at 2023-02-28v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥28.8bn | at 2022-02-28v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥34.2bn | at 2026-02-28 | Standalone | Cash and deposits |
| Cash and deposits | ¥31.7bn | at 2025-02-28 | Standalone | Cash and deposits |
| EPS (basic) | ¥47.88 | 2025-03-01 → 2026-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.47 | 2024-03-01 → 2025-02-28 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.04 | 2023-03-01 → 2024-02-29v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥56.05 | 2022-03-01 → 2023-02-28v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥53.37 | 2021-03-01 → 2022-02-28v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥47.87 | 2025-03-01 → 2026-02-28 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥83.41 | 2024-03-01 → 2025-02-28 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥74.9 | 2023-03-01 → 2024-02-29v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥55.95 | 2022-03-01 → 2023-02-28v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥53.27 | 2021-03-01 → 2022-02-28v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥17 | 2025-03-01 → 2026-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥17 | 2024-03-01 → 2025-02-28 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥135 | 2023-03-01 → 2024-02-29v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥135 | 2022-03-01 → 2023-02-28v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥65 | 2021-03-01 → 2022-02-28v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥371.53 | at 2026-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥362.43 | at 2025-02-28 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥295.55 | at 2024-02-29v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥215.47 | at 2023-02-28v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥166.34 | at 2022-02-28v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 60.7% | at 2026-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.6% | at 2025-02-28 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 54.2% | at 2024-02-29v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.3% | at 2023-02-28v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.1% | at 2022-02-28v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 13.0% | 2025-03-01 → 2026-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 25.4% | 2024-03-01 → 2025-02-28 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 29.6% | 2023-03-01 → 2024-02-29v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 29.4% | 2022-03-01 → 2023-02-28v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 37.8% | 2021-03-01 → 2022-02-28v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 176,400,000 | at 2026-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 176,400,000 | at 2025-02-28 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,640,000 | at 2024-02-29v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,640,000 | at 2023-02-28v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 17,640,000 | at 2022-02-28v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 259 | at 2026-02-28 | Standalone | Number of employees |
| Employees | 244 | at 2025-02-28 | Standalone | Number of employees |
| Employees | 240 | at 2024-02-29v | Standalone | Number of employees |
| Employees | 229 | at 2023-02-28v | Standalone | Number of employees |
| Employees | 222 | at 2022-02-28v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 51
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | revenue | 2025-03-01 → 2026-02-28 | −¥62m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-03-01 → 2026-02-28 | −¥62m |
| Reconciling Itemsreconciling | segment assets | at 2026-02-28 | ¥34.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-03-01 → 2026-02-28 | −¥862m |
| Life Sciencereportable segment | capex | 2025-03-01 → 2026-02-28 | ¥70m |
| Life Sciencereportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥64m |
| Life Sciencereportable segment | employees | at 2026-02-28 | 50 pure |
| Life Sciencereportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥1.2bn |
| Life Sciencereportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥1.2bn |
| Life Sciencereportable segment | segment assets | at 2026-02-28 | ¥3.3bn |
| Life Sciencereportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥13m |
| Semiconductor And Flat Panel Displayreportable segment | capex | 2025-03-01 → 2026-02-28 | ¥4.9bn |
| Semiconductor And Flat Panel Displayreportable segment | depreciation | 2025-03-01 → 2026-02-28 | ¥3.1bn |
| Semiconductor And Flat Panel Displayreportable segment | employees | at 2026-02-28 | 4385 pure |
| Semiconductor And Flat Panel Displayreportable segment | revenue | 2025-03-01 → 2026-02-28 | ¥127.7bn |
| Semiconductor And Flat Panel Displayreportable segment | revenue external | 2025-03-01 → 2026-02-28 | ¥127.6bn |
| Semiconductor And Flat Panel Displayreportable segment | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥62m |
| Semiconductor And Flat Panel Displayreportable segment | segment assets | at 2026-02-28 | ¥159.8bn |
| Semiconductor And Flat Panel Displayreportable segment | segment profit | 2025-03-01 → 2026-02-28 | ¥32.0bn |
| —segment total | capex | 2025-03-01 → 2026-02-28 | ¥5.0bn |
| —segment total | depreciation | 2025-03-01 → 2026-02-28 | ¥3.1bn |
| —segment total | revenue | 2025-03-01 → 2026-02-28 | ¥128.9bn |
| —segment total | revenue external | 2025-03-01 → 2026-02-28 | ¥128.8bn |
| —segment total | revenue intersegment | 2025-03-01 → 2026-02-28 | ¥62m |
| —segment total | segment assets | at 2026-02-28 | ¥163.1bn |
| —segment total | segment profit | 2025-03-01 → 2026-02-28 | ¥32.0bn |
| Reconciling Itemsreconciling | revenue | 2024-03-01 → 2025-02-28 | −¥111m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-03-01 → 2025-02-28 | −¥111m |
| Reconciling Itemsreconciling | segment assets | at 2025-02-28 | ¥31.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-03-01 → 2025-02-28 | −¥1.1bn |
| Life Sciencereportable segment | capex | 2024-03-01 → 2025-02-28 | ¥128m |
| Life Sciencereportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥50m |
| Life Sciencereportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥1.1bn |
| Life Sciencereportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥1.1bn |
| Life Sciencereportable segment | segment assets | at 2025-02-28 | ¥3.2bn |
| Life Sciencereportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥122m |
| Semiconductor And Flat Panel Displayreportable segment | capex | 2024-03-01 → 2025-02-28 | ¥2.5bn |
| Semiconductor And Flat Panel Displayreportable segment | depreciation | 2024-03-01 → 2025-02-28 | ¥2.8bn |
| Semiconductor And Flat Panel Displayreportable segment | revenue | 2024-03-01 → 2025-02-28 | ¥123.4bn |
| Semiconductor And Flat Panel Displayreportable segment | revenue external | 2024-03-01 → 2025-02-28 | ¥123.3bn |
| Semiconductor And Flat Panel Displayreportable segment | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥111m |
| Semiconductor And Flat Panel Displayreportable segment | segment assets | at 2025-02-28 | ¥152.8bn |
| Semiconductor And Flat Panel Displayreportable segment | segment profit | 2024-03-01 → 2025-02-28 | ¥33.0bn |
| —segment total | capex | 2024-03-01 → 2025-02-28 | ¥2.7bn |
| —segment total | depreciation | 2024-03-01 → 2025-02-28 | ¥2.8bn |
| —segment total | revenue | 2024-03-01 → 2025-02-28 | ¥124.5bn |
| —segment total | revenue external | 2024-03-01 → 2025-02-28 | ¥124.4bn |
| —segment total | revenue intersegment | 2024-03-01 → 2025-02-28 | ¥111m |
| —segment total | segment assets | at 2025-02-28 | ¥156.1bn |
| —segment total | segment profit | 2024-03-01 → 2025-02-28 | ¥33.1bn |
| Semiconductor And Flat Panel Displayreportable segment | employees | at 2026-02-28 | 259 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,595
| Item | Context | Value | Unit |
|---|---|---|---|
| Research and development expenses sga | CurrentYearDuration | 1927000000 | JPY |
| Provision of allowance for doubtful accounts sga | Prior1YearDuration | 122000000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYearDuration | 36000000 | JPY |
| Taxes and dues sga | Prior1YearDuration | 480000000 | JPY |
| Taxes and dues sga | CurrentYearDuration | 508000000 | JPY |
| Commission fee sga | Prior1YearDuration | 1833000000 | JPY |
| Commission fee sga | CurrentYearDuration | 1765000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 1690000000 | JPY |
| Amortization of goodwill sga | CurrentYearDuration | 3117000000 | JPY |
| Research and development expenses sga | Prior1YearDuration | 1242000000 | JPY |
| Research and development expenses sga | CurrentYearDuration | 1927000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E02328-000SemiconductorAndFlatPanelDisplayReportableSegmentMember | 123331000000 | JPY |
| Revenues from external customers | Prior1YearDuration_jpcrp030000-asr_E02328-000LifeScienceReportableSegmentMember | 1074000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReportableSegmentsMember | 124406000000 | JPY |
| Revenues from external customers | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YearDuration | 124406000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E02328-000SemiconductorAndFlatPanelDisplayReportableSegmentMember | 111000000 | JPY |
| Transactions with other segments | Prior1YearDuration_jpcrp030000-asr_E02328-000LifeScienceReportableSegmentMember | － | JPY |
| Transactions with other segments | Prior1YearDuration_ReportableSegmentsMember | 111000000 | JPY |
| Transactions with other segments | Prior1YearDuration_ReconcilingItemsMember | -111000000 | JPY |
| Transactions with other segments | Prior1YearDuration | － | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E02328-000SemiconductorAndFlatPanelDisplayReportableSegmentMember | 123442000000 | JPY |
| Net sales | Prior1YearDuration_jpcrp030000-asr_E02328-000LifeScienceReportableSegmentMember | 1074000000 | JPY |
| Net sales | Prior1YearDuration_ReportableSegmentsMember | 124517000000 | JPY |
| Net sales | Prior1YearDuration_ReconcilingItemsMember | -111000000 | JPY |
| Net sales | Prior1YearDuration | 124406000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E02328-000SemiconductorAndFlatPanelDisplayReportableSegmentMember | 32952000000 | JPY |
| Operating income | Prior1YearDuration_jpcrp030000-asr_E02328-000LifeScienceReportableSegmentMember | 122000000 | JPY |
| Operating income | Prior1YearDuration_ReportableSegmentsMember | 33075000000 | JPY |
| Operating income | Prior1YearDuration_ReconcilingItemsMember | -1051000000 | JPY |
| Operating income | Prior1YearDuration | 32024000000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E02328-000SemiconductorAndFlatPanelDisplayReportableSegmentMember | 152842000000 | JPY |
| Assets | Prior1YearInstant_jpcrp030000-asr_E02328-000LifeScienceReportableSegmentMember | 3242000000 | JPY |
| Assets | Prior1YearInstant_ReportableSegmentsMember | 156084000000 | JPY |
| Assets | Prior1YearInstant_ReconcilingItemsMember | 31653000000 | JPY |
| Assets | Prior1YearInstant | 187738000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E02328-000SemiconductorAndFlatPanelDisplayReportableSegmentMember | 2796000000 | JPY |
| Depreciation segment information | Prior1YearDuration_jpcrp030000-asr_E02328-000LifeScienceReportableSegmentMember | 50000000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReportableSegmentsMember | 2847000000 | JPY |
| Depreciation segment information | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Depreciation segment information | Prior1YearDuration | 2847000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E02328-000SemiconductorAndFlatPanelDisplayReportableSegmentMember | 1683000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_jpcrp030000-asr_E02328-000LifeScienceReportableSegmentMember | 7000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_ReportableSegmentsMember | 1690000000 | JPY |
| Amortization of goodwill sga | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
| Amortization of goodwill sga | Prior1YearDuration | 1690000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E02328-000SemiconductorAndFlatPanelDisplayReportableSegmentMember | 2537000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_jpcrp030000-asr_E02328-000LifeScienceReportableSegmentMember | 128000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_ReportableSegmentsMember | 2665000000 | JPY |
| Increase in property plant and equipment and intangible assets | Prior1YearDuration_ReconcilingItemsMember | － | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |